格隆汇1月23日｜疫苗生产商Moderna(MRNA.US)盘前跌3.9%。据彭博消息，Moderna公司首席执行官表 示，由于美国官员对疫苗接种的反对声浪日益高涨，该公司不打算投资新的后期疫苗试验。"如果无法 进入美国市场，就无法获得投资回报，"斯特凡·班塞尔在瑞士达沃斯世界经济论坛期间表示。他指出， 监管方面的延误以及美国卫生官员缺乏支持，使得潜在市场规模"大幅缩小"。 | MRNA Moderna | | | | --- | --- | --- | | 51870 + +2.060 +4.14% | | 收盘价 01/22 16:00 美东 | | 49.840 ↓ -2.030 -3.91% | | 盘前价 01/23 04:13 美东 | | 三 7 24 5 8 9 日 ♥ 白 一 白 | | ● 快捷交易 | | 最高价 55.200 | 开盘价 50.240 | 成交量 3424.35万 | | 最低价 50.050 | 昨收价 49.810 | 成交额 18.15亿 | | 平均价 52.993 | 市盈率门M 亏损 | 总市值 202.65亿 (--) | | 振 幅 10.34% | 市 ...

Market Overview - U.S. stock futures declined slightly after major indices posted gains for two consecutive days [1] - The Dow Jones, S&P 500, Nasdaq 100, and Russell 2000 all showed minor declines in premarket trading [4] Economic Data - U.S. Final GDP for Q3 was reported at 4.4%, exceeding estimates of 4.3% [2] - The Personal Consumption Expenditures (PCE) price index increased by 2.8% year-over-year, aligning with expectations [2] - The 10-year Treasury bond yield was at 4.23%, while the two-year bond yield was at 3.60% [3] - Market expectations indicate a 95% likelihood that the Federal Reserve will maintain current interest rates in January [3] Stocks in Focus - **Capital One Financial Corp.**: Shares fell 3.31% in pre-market trading after Q4 results missed analyst estimates [6] - **Revelation Biosciences Inc.**: Stock surged 38.11% after announcing an agreement with the FDA for its drug Gemini [6] - **Intel Corp.**: Shares dropped over 12% due to a weak Q1 outlook that fell short of expectations [6] - **CSX Corp.**: Stock rose 2.99% despite missing consensus estimates on both revenue and earnings [6] Sector Performance - Energy, materials, consumer discretionary, and health care sectors led gains in the S&P 500 on Thursday [7] Analyst Insights - Bank of America's fund manager survey indicates institutional investors are the most bullish since 2021, with 38% expecting stronger global growth [9] - The survey included 196 participants managing $575 billion in assets, showing a significant increase in equity allocations [9] - BofA's Bull & Bear Indicator rose to 9.4, indicating high optimism in the market [10] Commodities and Crypto - Crude oil futures increased by 1.03% to approximately $59.97 per barrel [11] - Gold Spot price rose by 0.19% to around $4,918.76 per ounce [11] - Bitcoin traded 0.40% lower at $89,258.41 per coin [11]

Core Viewpoint - Alpha Tau Medical (DRTS) is positioned as a unique technology with potential for significant growth, particularly looking towards 2026 as a pivotal year for the company [1] Company Overview - Alpha Tau Medical has had an eventful start to the year, indicating active developments and potential advancements in its technology [1] Investment Position - There is a beneficial long position in the shares of DRTS, suggesting confidence in the company's future performance and growth potential [1]

Biotech stocks saw notable upward momentum in Thursday's after-hours trading session, with several names posting strong percentage gains despite the absence of fresh company-specific developments.Coherus Oncology, Inc. (CHRS) climbed 9.09% to close at $1.73, adding $0.14 in extended trading. Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a gain of $1.14. Cue Biopharma, Inc. (CUE) advanced 9.37% to $0.40, rising $0.034 in after-hours action. Alpha Tau Medical Ltd. (D ...

Group 1 - American Tungsten & Antimony is set to list on NASDAQ in Q2 2026, with Deutsche Bank facilitating the process, amid renewed interest in critical minerals due to Trump's initiatives [2] - West Wits Mining, an African-based gold explorer, is experiencing increased market interest and liquidity as gold prices approach US$5,000 per ounce due to geopolitical factors [3] - Nyrada Inc, a US-based biotech listed on ASX, has seen a remarkable 1280% increase over the past year, with a recent quarterly report contributing to a further 10% jump in share price [4] Group 2 - PLS Group is back in focus as lithium carbonate benchmarks rise to levels not seen since 2023, potentially leading to dividend payments [4] - Australian Strategic Materials is facing mixed reactions as Energy Fuels, a US-based uranium and critical minerals player, seeks to acquire the company at a premium, with board agreement [5] - Lumos Diagnostics has posted a significant 450% gain over the past year, making it a topic of ongoing discussion among investors [5]

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-thera ...

New York, New York--(Newsfile Corp. - January 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

Janux Therapeutics, Inc. (NASDAQ:JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE:BMY) .San Diego-based Janux will receive up to $50 million in upfront and near-term milestone payments, with potential total payments reaching approximately $800 million, including royalties on global product sales.The collaboration allows Janux to complete preclinical development up to Investigational New Drug (IND) submission, while Bristol Myers Squibb ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Guardant Health Inc.’s (NASDAQ:GH) Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with Braftovi (encorafenib) in combination with cetuximab and chemotherapy.The accelerated approval for Braftovi was supported by data from Pfizer Inc.’s (NYSE:PFE) Phase 3 BREAKWATER trial.DataThe study showed that treatment with encorafenib and cetuximab p ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I and other columnists have opined in recent quarters on how the current trajectory of the AI Revolution is eerily reminiscent of the last innings of the Internet Boom. Now personally I try hard toBret Jensen has over 13 years as a mark ...